The Oncology Nursing Society (ONS) hosted a meeting of Safe Handling of Hazardous Drugs Association Stakeholders where organizational representatives voiced the concerns of their members about safe handling.
story and image
ONS hosted 14 nurses and association professionals at a Safe Handling of Hazardous Drugs Association Stakeholders meeting on February 16, 2015, at the Paul Hastings, LLP office in Washington, DC. Representatives from five professional organizations participated with ONS members and staff to generate discussion on the issues surrounding safe handling of hazardous drugs.
The objectives for the meeting were to outline key issues in the implementation of standards followed in the safe handling of hazardous drugs, and to provide consensus recommendations regarding the implementation of the U.S. Pharmacopeial Convention's General Chapter 800 Hazardous Drugs–Handling in Healthcare Settings.
The meeting provided the opportunity for organizational representatives to voice the concerns of their membership regarding safe handling. Presentations and discussions reviewed the literature available and member concerns regarding engineering controls, personal protective equipment (PPE), medical surveillance, attitudes, beliefs, and financial concerns. During this discussion, common ground was identified and summarized in the following consensus statements.
This group agreed that it will
- Create and continuously promote a culture of patient and healthcare safety.
- Provide resources, including templates, to promote compliance with implementing safe handling.
- Reach a consensus on critical definitions (e.g., what defines a spill).
- Include practitioner input in facility design.
- Develop resources for how to choose PPE and closed-system transfer devices.
- Include worker safety standards in the next iteration of chemotherapy and biotherapy safety standards.
- Provide free access to a medical surveillance questionnaire template.
Participants will discuss the meeting with the organizations they represent.
- Organizations will share their response to the USP Chapter 800 draft prior to submission to reinforce the shared points with a shared voice.
- Approval of the joint position statement should be obtained in February.
- The group will design a plan to address consensus statements.
Melissa A. McDiarmid, MD, MPH, DABT (invited presenter)
Bona Benjamin, B.S.Pharm., Representing: American Society of Health-System Pharmacists (ASHP)
Patricia Kienle, RPh, MPA, FASHP, Representing: American Society of Health-System Pharmacists
Deborah Kamin, RN, PhD, Representing: American Society of Clinical Oncology (ASCO)
Steven K. Stranne, MD, JD, Representing: American Society of Clinical Oncology
Ryan Forrey, PharmD, MS, FASHP, Representing: Hematology/Oncology Pharmacists Association (HOPA)
Kristin Belderson, DNP, MS, RN, CPON, Representing: Association of Pediatric Hematology/Oncology Nurses (APHON)
Leah Ralph, Manager, Representing: Association of Community Cancer Centers (ACCC)
Martha Polovich, PhD, RN, AOCN®
Marlon Garzo Saria, MSN, RN, AOCNS®
Michele R. McCorkle Dietz, RN, MSN, Executive Director, External Relations and Business Development
Michele Galioto, RN, MSN, Director, ONS Education
Kristine B. LeFebvre, MSN, RN, AOCN®, Oncology Clinical Specialist, Education Team
Alec Stone, MA, MPA, Director of Health Policy